KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 2

Effect of Smoking Status on Hematological Toxicities andEffectiveness of First-line Platinum-based ChemotherapyAdministered to Patients with Non-small-cell Lung Cancer

Nilay Şengül SAMANCI
Nebi Serkan DEMİRCİ
Fuat Hulusi DEMİRELLİ
Emir ÇELİK
Ezgi DEĞERLİ
Onur Erk TAPARLİ
Sayfa
189–195
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Results: 26 (37.1%) of the patients were former smokers, 44 (62.9%) of the patients were current smokers. 13 (18.6%)patients quit smoking

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: In this paper we thus aimed to determine whether smoking during chemotherapy affects the outcome ofnon-small cell lung cancer (NSCLC) treatment and increases hematological side effects.
📊
Temel Bulgular & Veri:Methods: We have reviewed 70 stage-IV NCSLC patients, who had received chemotherapy as the firstline therapy.Smoking status before and during the administration of the firstline therapy, therapeutic regimens, clinical outcomes,hematological adverse events, and infections that develop during the chemotherapy were investigated.
💡
Sonuç & Katkı:Results: 26 (37.1%) of the patients were former smokers, 44 (62.9%) of the patients were current smokers. 13 (18.6%)patients quit smoking
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: In this paper we thus aimed to determine whether smoking during chemotherapy affects the outcome ofnon-small cell lung cancer (NSCLC) treatment and increases hematological side effects. Methods: We have reviewed 70 stage-IV NCSLC patients, who had received chemotherapy as the firstline therapy.Smoking status before and during the administration of the firstline therapy, therapeutic regimens, clinical outcomes,hematological adverse events, and infections that develop during the chemotherapy were investigated. Results: 26 (37.1%) of the patients were former smokers, 44 (62.9%) of the patients were current smokers. 13 (18.6%)patients quit smoking

🔖

Bu Makaleye Atıf Yap

SAMANCI, N. Ş., DEMİRCİ, N. S., DEMİRELLİ, F. H., ÇELİK, E., DEĞERLİ, E., TAPARLİ, O. E. (2022). Effect of Smoking Status on Hematological Toxicities andEffectiveness of First-line Platinum-based ChemotherapyAdministered to Patients with Non-small-cell Lung Cancer. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 2, 189–195. https://ajindex.com/articles/508590

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Mao Y, Yang D, He J, Krasna MJ. Epidemiology of lung cancer. Surg Oncol Clin N Am 2016;25:439–45
  2. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer: lung cancer. N Engl J Med 2008 25;359:1367–80. 3. de Kock I, Mirhosseini M, Lau F, Thai V, Downing M, Quan H, et al. Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. J Palliat Care 2013;29:163–9
  3. U.S. Department of Health and Human Services. Common terminology criteria for adverse events v4.03 (CTCAE)2010. Available at: https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf. Accessed Jun 7, 2015
  4. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 2016;62:132–7
  5. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004;125:27–37
  6. Toh CK, Wong EH, Lim WT, Leong SS, Fong KW, Wee J, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest 2004;126:1750–6
  7. Kawai H, Tada A, Kawahara M, Nakai K, Maeda H, Saitou R, et al; Japan National Hospital Study Group for Lung Cancer. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer--a multicenter study. Lung Cancer 2005;49:63–70
  8. Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer 2006;53:375–80
  9. Peppone LJ, Mustian KM, Morrow GR, Dozier AM, Ossip DJ, Janelsins MC, et al. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist 2011;16:1784–92
  10. Baser S, Shannon VR, Eapen GA, Jimenez CA, Onn A, Lin E, et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 2006;130:1784–90
  11. Liu J, Liang Q, Frost-Pineda K, Muhammad-Kah R, Rimmer L, Roethig H, et al. Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol Biomarkers Prev 2011;20:1760–9
  12. Swamınathan A, K Amitkumar, S Ganapathy,